References

1. Shetty N, Friedman JH, Kieburtz K, Marshall FJ, Oakes D. The placebo response in Parkinson's disease. Parkinson Study Group. Clin Neuropharmacol 1999;22(4):207-212.

2. Goetz CG, Leurgans S, Raman R, Stebbins GT. Objective changes in motor function during placebo treatment in PD. Neurology 2000;54(3):710-714.

3. Goetz CG, Laska E, Hicking C, et al. Placebo influences on dyskinesia in Parkinson's disease. Mov Disord 2008;23(5):700-707.

4. Goetz CG, Wuu J, McDermott MP, et al. Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord 2008;23(5):690-699.

5. Watts RL, Freeman TB, Hauser RA, et al. A double-blind, randomized, controlled, multicenter clinical trial of the safety and efficacy of stereotaxic intrastriatal implantation of fetal porcine ventral mesencephalic tissue (Neurocelltm-PD) vs imitation surgery in patients with Parkinson disease (PD). Parkinsonism Relat Disord 2001;7(Suppl 1):S87.

6. Olanow CW, Goetz CG, Kordower JH, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003;54(3):403-414.

7. Bartus RT, Weinberg MS, Samulski RJ. Parkinson's disease gene therapy: success by design meets failure by efficacy. Mol Ther 2014;22(3):487-497.

8. LeWitt PA, Rezai AR, Leehey MA, et al. AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomized trial. Lancet Neurol 2011;10(4):309-319.

9. Christine CW, Starr PA, Larson PS, et al. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 2009;73(20):1662-1669.

10. Muramatsu SI, Fujimoto KI, Kato S, et al. A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease. Mol Ther 2010;18(9):1731-1735.

11. Bartus RT, Baumann TL, Siffert J, et al. Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. Neurology 2013;80(18):1698-1701.

12. McRae C, Cherin E, Yamazaki TG, et al. Effects of perceived treatment on quality of life and medical outcomes in a double-blind placebo surgery trial. Arch Gen Psychiatry 2004;61(4):412-420.

13. Benedetti F, Frisaldi E, Carlino E, et al. Teaching neurons to respond to placebos. J Physiol 2016;594(19):5647-5660.

14. de la Fuente-Fernández R, Ruth TJ, Sossi V, Schulzer M, Calne DB, Stoessl AJ. Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 2001;293(5532):1164-1166.

15. Benedetti F, Colloca L, Torre E, et al. Placebo-responsive Parkinson patients show decreased activity in single neurons of subthalamic nucleus. Nat Neurosci 2004;7(6):587-588.

16. Benedetti F, Lanotte M, Colloca L, Ducati A, Zibetti M, Lopiano L. Electrophysiological properties of thalamic, subthalamic and nigral neurons during the anti-parkinsonian placebo response. J Physiol 2009;587(PT 15):3869-3883.

17. Frisaldi E, Carlino E, Lanotte M, Lopiano L, Benedetti F. Characterization of the thalamic-subthalamic circuit involved in the placebo response through single-neuron recording in Parkinson patients. Cortex 2014;60:3-9.

18. Pollo A, Torre E, Lopiano L, et al. Expectation modulates the response to subthalamic nucleus stimulation in Parkinsonian patients. Neuroreport 2002;13(11):1383-1386.

19. Benedetti F, Pollo A, Lopiano L, Lanotte M, Vighetti S, Rainero I. Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo/nocebo responses. J Neurosci 2003;23(10):4315-4323.

20. Mercado R, Constantoyannis C, Mandat T, et al. Expectation and the placebo effect in Parkinson's disease patients with subthalamic nucleus deep brain stimulation. Mov Disord 2006;21(9):1457-1461.

21. Zappia M, Montesanti R, Colao R, Quattrone A. Usefulness of movement time in the assessment of Parkinson's disease. J Neurol 1994;241(9):543-550.

22. Benedetti F, Carlino E, Piedimonte A. Increasing uncertainty in CNS clinical trials: the role of placebo, nocebo, and Hawthorne effects. Lancet Neurol 2016;15(7):736-747.

Ferric Carboxymaltose in Patients With Restless Legs Syndrome and Nonanemic Iron Deficiency: A Randomized Trial

Claudia Trenkwalder, MD,[1,2]* Juliane Winkelmann, MD,[3,4,5] Wolfgang Oertel, MD,[4,6] Garth Virgin, MD, PhD,[7] Bernard Roubert, MSc,[7] Anna Mezzacasa, PhD,[7] on behalf of the FCM-RLS Study Investigators

[1]Department of Neurosurgery, University Medical Center, Göttingen, Germany [2]Paracelsus-Elena Klinik, Kassel, Germany [3]Neurologische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München, Munich, Germany [4]Institut für Neurogenomik, Helmholtz Zentrum München, Munich, Germany [5]Munich Cluster for Systems Neurology (SyNergy), Munich, Germany [6]Department of Neurology, Philipps-University Marburg, Marburg, Germany [7]Vifor Pharma, Glattbrugg, Switzerland

Abstract

Background: Compromised iron status is important in restless legs syndrome pathophysiology. We compared the efficacy and tolerability of ferric carboxymaltose (single intravenous dose) versus placebo for restless legs syndrome treatment in iron-deficient nonanemic patients.

Methods: Patients with moderate to severe restless legs syndrome and serum ferritin < 75 μg/L (or serum ferritin 75-300 μg/L and transferrin saturation < 20%) were randomized to ferric carboxymaltose (1000 mg iron) or placebo. Mean change difference between ferric carboxymaltose and placebo in International Restless Legs Syndrome Severity Scale score from baseline to week 4 was the primary end point; week 12 was a secondary end point.

Results: Ferric carboxymaltose treatment (n = 59) led to nonsignificant improvement over placebo (n = 51) in International Restless Legs Syndrome Severity Scale score at week 4 (difference [95% confidence interval], -2.5 [-5.93 to 1.02], $P = 0.163$), reaching significance by week 12 (-4.66 [-8.59 to -0.73], $P = 0.021$).

Conclusions: In patients who responded to treatment, ferric carboxymaltose may require more time to stabilize restless legs syndrome than previously assumed. © 2017 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

Key Words: restless legs syndrome; intravenous iron; iron deficiency; ferric carboxymaltose; clinical trial

Restless legs syndrome (RLS) pathophysiology is still only partly understood, with the involvement of the dopaminergic system still under debate.[1] However, genetic studies thus far have failed to link dopamine pathology to RLS.[2] Compromised iron status is an important disorder, possibly contributing to the cause of RLS.[3] However, the causal relationship still remains unclear, and there is much debate about how to adequately assess iron status in RLS patients.[4-8] The potential relationship between low iron status and RLS has led to increased interest in the use of iron replacement therapy to treat this disorder.[1] Study results have varied, most likely because of the different iron formulations and dosages used, as well as study design. Although some previous studies excluded anemic patients,[7] all studies to date have included patients of varied iron status, but have not provided clear evidence about which RLS patients might benefit most from iron treatment.[6-11]

Previously, a single treatment of ferric carboxymaltose (FCM) provided significant and prolonged reduction (>24 weeks) in RLS symptoms, with minimal adverse events (AEs) in 2 small cohorts of patients.[6,12] FCM has been shown to also provide significant reduction in RLS symptoms in pregnant women.[11] However, these studies included patients with a broad range of serum ferritin levels, making it difficult to establish any relationship between pretreatment serum ferritin level and response to therapy.[6,12]

This study compared the efficacy and tolerability of a single 1000-mg infusion of intravenous iron as FCM versus placebo, as a treatment for RLS in patients with impaired iron status.

Methods
Patients

Patients aged ≥18 years weighing ≥50 kg with moderate to severe RLS (International RLS Severity Scale [IRLS] total score ≥15), normal hemoglobin levels (women, ≥11.5 g/dL; men, ≥12.5 g/dL), and

---

*Corresponding author: Claudia Trenkwalder, MD, Paracelsus-Elena Klinik, Klinikstraße 16, 34128 Kassel, Germany; ctrenkwalder@med. uni-goettingen.de

TABLE 1. Patient demographics and baseline characteristics

Variable[a]	Ferric carboxymaltose (n = 59)	Placebo (n = 51)
Age, years	53.0 (15.7)	55.5 (15.9)
Age category, n (%)		
<65 years	41 (69.5)	35 (68.6)
65-74 years	15 (25.4)	11 (21.6)
75-84 years	3 (5.1)	5 (9.8)
Female, n (%)	48 (81.4)	42 (82.4)
Weight, kg	73.88 (16.58)	73.89 (13.10)
Height, cm	166.1 (8.64)	167.0 (7.71)
BMI, kg/m²	26.77 (5.70)	26.46 (4.09)
Previous dopaminergic treatment, n (%)	31 (53.4)	23 (44.2)
Serum ferritin, μg/L	41.93 (34.55)	48.85 (45.95)
TSAT, %	18.49 (7.88)	21.14 (9.19)
IRLS total score	25.9 (5.65)	26.0 (5.78)
CGI-Item 1 severity score	4.8 (0.87)	4.7 (0.74)
RLS-6		
Sleep satisfaction	7.2 (2.53)	7.2 (2.52)
Severity when falling asleep	6.8 (2.66)	6.2 (3.03)
Severity during the night	5.9 (3.06)	5.7 (3.18)
Severity during the day, at rest	4.5 (3.06)	4.3 (2.88)
Severity during the day, active	1.8 (2.30)	2.5 (2.69)
Daytime tiredness	5.9 (2.60)	5.6 (3.07)

[a]Mean (standard deviation) unless otherwise stated.
BMI, body mass index; CGI, Clinical Global Impressions; IRLS, International Restless Legs Scale; RLS-6, Restless Legs Syndrome-6; TSAT, transferrin saturation.

serum ferritin <75 μg/L were eligible for this study (patients were also included if serum ferritin was between 75 and 300 μg/L and transferrin saturation [TSAT] was <20%). All patients provided appropriate written informed consent. Further details can be found in the Supplementary Materials.

Study Design

This trial was a prospective phase 4 patient- and assessor-blind (the study nurse who administered the treatment was not blinded), placebo-controlled 12-week multicenter study (EudraCT number: 2013-000574-30). Eligible patients were randomized before the start of treatment to either a single intravenous dose of 1000 mg iron as ferric carboxymaltose or placebo by drip infusion over 15 ± 2 minutes on day 1 (see Supplementary Material). This study was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice guidelines. More details can be found in the Supplementary Materials.

Study Objectives and End Points

The primary objective of this study was to compare the efficacy of FCM versus placebo as treatment for RLS in iron-deficient nonanemic patients. The primary efficacy end point was the difference in mean change in IRLS score from baseline to week 4 between FCM therapy and placebo; change from baseline to week 12

FCM: n = 59 n = 59 n = 49 n = 45
Placebo: n = 50 n = 51 n = 39 n = 35

*P = 0.021
FCM, ferric carboxymaltose; IRLS, International Restless Legs Scale;
LS, least squares; SE, standard error.

FIG. 1. Changes over time in IRLS total score.

was a secondary efficacy end point. Mean change in serum ferritin and TSAT levels and tolerability were monitored throughout. Other secondary efficacy end points are described in the Supplementary Materials.

Assessments

Assessments were performed at baseline, weeks 1, 4, 8, and 12, and at the end of study (EOS; ie, week 12 or following earlier termination), unless otherwise stated. Efficacy was primarily assessed with the patient-based IRLS scale. Secondary assessments included the Clinical Global Impression scale items-1 and -2, the Patient Global Impression of Improvement Index, RLS-6 scale, and quality-of-life (QoL) questionnaire. Safety was assessed by monitoring the occurrence or increase in severity of AEs throughout the study and up to 30 days after administration of treatment or at last study visit, whichever was longer. More details can be found in the Supplementary Materials.

Statistical Analyses

The sample size (55 per treatment arm) was calculated assuming an improvement of IRLS total score of at least 4.5 in the FCM group compared with placebo at week 4,[6] using a standard deviation of 8 points, 5% 2-sided type I error, and 80% power. All efficacy analyses were conducted on the full analysis set (FAS), and safety and tolerability analyses were conducted on the safety set. For further details, please see Supplementary Materials.

Results

Patient Population

A total of 110 patients (mean $\pm$ SD age, 54.1 $\pm$ 15.8 years; 82% female; 49% previously received dopaminergic treatment; Table 1) from 13 sites (Finland, 3 [n =36]; Germany, 8 [n = 70]; Switzerland: 2 [n = 4]) were randomized to receive a single intravenous dose of FCM (n=59) or placebo (n=51) and included in the FAS (Suppl. Fig. 1). Patient demographics and baseline characteristics were similar between treatment arms (Table 1), and 87 patients (79%) completed the study.

Efficacy

The primary end point was not met after 4 weeks, with a change in IRLS (LS mean, last observation carried forward [LOCF]) of -7.7 (standard error [SE] = 1.1) for patients treated with FCM and -5.2 (SE = 1.2) for those treated with placebo (treatment difference, -2.9; 95% confidence interval [CI], -5.93 to 1.02; P = 0.163; Fig. 1). However, the mean decrease in IRLS total score from baseline was greater with FCM versus placebo at all study visits and led to a significant improvement by week 12 (FCM, -9.6 $\pm$ 1.4; placebo, -5.0 $\pm$ 1.5; treatment difference, -4.66 [95%CI, -8.59 to -0.73]; P = 0.021; Fig. 1). Results from most other secondary end points were also significantly in favor of FCM (for other RLS symptom severity, QoL, and sleep results, see Supplementary Materials).

Patient Iron Status

Changes in serum ferritin and TSAT levels from baseline were significantly increased with FCM treatment versus placebo throughout the study ($P < 0.001$). There was a significant correlation between baseline TSAT level and IRLS improvement with FCM treatment at week 4 ($r = 0.37$; $P = 0.006$) and EOS ($r = 0.28$; $P = 0.031$). There was no correlation between baseline serum ferritin level or increased iron parameter level and IRLS improvement.

Tolerability

Overall, 33 treatment-emergent AEs (TEAEs) were reported in 23 patients (FCM, 16 patients, 27.1%; placebo, 7 patients, 13.7%; Suppl. Table 3), the majority of which were mild or moderate in severity. Severe TEAEs were experienced by 4 patients in the FCM group and 2 with placebo. Serious AEs were reported in 2 patients, 1 from each treatment group, which led to their withdrawal from the study. No hypersensitivity reactions, anaphylactoid reactions, or deaths were reported. For additional details, please refer to the Supplementary Materials.

Discussion

The results of this study in iron-deficient nonanemic patients showed that a single 1000-mg dose of intravenous iron as FCM provides nonsignificant differences in IRLS after 4 weeks of treatment (primary end point) compared with placebo; however, FCM provides a significant and clinically meaningful difference[13,14] after 12 weeks (treatment difference, -4.66; P = 0.021). Unlike other treatments, which may be administered several times over the trial period,[6,8] FCM was administered as a single intravenous dose. This may have increased the likelihood of withdrawal if patients were administered placebo treatment or possibly had a noniron-sensitive RLS phenotype and could not tolerate RLS symptoms over time. Nevertheless, patients who did respond to FCM treatment achieved the greatest improvements in IRLS scores at varying times, suggesting either an early or late responder in iron-sensitive IRLS phenotypes. This time-delayed response to FCM in the current study is different compared with trials examining dopaminergic or opioidergic agents. In support of the IRLS assessment, most other RLS symptom severity and QoL scores were also significantly improved with FCM treatment by week 12.

RLS symptom severity assessments such as IRLS, CGI, and even RLS-6 are gold standard methods for measuring RLS treatment efficacy.[15-17] IRLS findings observed in the current study are similar to those seen in previous randomized, placebo-controlled trials. Allen et al reported a significant 5-point difference in mean IRLS total score between FCM and placebo at week 4 (P = 0.049).[6] Similarly, Cho et al also reported a significant 12-point difference in IRLS score between FCM and placebo at week 6 (P = 0.03).[12] However, unlike the current study, there were no serum ferritin threshold inclusion criteria in either study, making it difficult to determine which patients would benefit from treatment.[6,12]

Severity of RLS is worse when at rest during the day and evening,[17] which is significantly alleviated with FCM treatment, as reflected in RLS-6 scores for both at rest during the day, and in the evening. The nonsignificant improvements in RLS-6 for "severity during the day when active" further support the suggestion that only RLS-characteristic symptoms were improved with FCM.

Although the causal relationship between compromised iron status and RLS remains unclear, our findings support a role for iron replacement therapy in the treatment of RLS. Iron has important roles in oxygen metabolism and energy capacity,[18] and RLS is often associated with conditions involving hypoxia.[19-21] Notably, baseline TSAT levels correlated significantly with improvement in IRLS scores at week 4 and EOS. Patients with a lower baseline TSAT value appeared to have a greater improvement in IRLS score, suggesting that patients who are more iron deficient may benefit from FCM treatment. The maintenance of higher iron levels with FCM may boost oxidative metabolism, resulting in the significant improvements observed in this study.

Conclusions

Although the primary efficacy end point at week 4 was not met, a single 1000-mg dose of iron as FCM could provide significant improvements in RLS symptoms after 12 weeks in this iron-deficient nonanemic RLS population. The mechanisms underlying this effect are still not fully understood; for example, early versus late responders, or lack of response to iron treatment, could reflect a phenotype of patients with causes of RLS independent of iron status. Furthermore, large-scale studies are needed to identify subgroups of patients who will benefit most from FCM treatment. ∎

References

1. Earley CJ, Uhl GR, Clemens S, Ferre S. Connectome and molecular pharmacological differences in the dopaminergic system in restless legs syndrome (RLS): plastic changes and neuroadaptations that may contribute to augmentation. Sleep Med 2017;31:71-77.

2. Winkelmann J, Polo O, Provini F, et al. Genetics of restless legs syndrome (RLS): State-of-the-art and future directions. Mov Disord 2007;22(Suppl 18):S449-S458.

3. Trenkwalder C, Allen R, Hogl B, Paulus W, Winkelmann J. Restless legs syndrome associated with major diseases: a systematic review and new concept. Neurology 2016;86:1336-1343.

4. Manconi M, Govoni V, De VA, et al. Pregnancy as a risk factor for restless legs syndrome. Sleep Med 2004;5:305-308.

5. Trenkwalder C, Winkelmann J, Inoue Y, Paulus W. Restless legs syndrome-current therapies and management of augmentation. Nat Rev Neurol 2015;11:434-445.

6. Allen RP, Adler CH, Du W, Butcher A, Bregman DB, Earley CJ. Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial. Sleep Med 2011;12:906-913.

7. Earley CJ, Horska A, Mohamed MA, Barker PB, Beard JL, Allen RP. A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome. Sleep Med 2009;10:206-211.

8. Grote L, Leissner L, Hedner J, Ulfberg J. A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Mov Disord 2009;24:1445-1452.

9. Nordlander NB. Therapy in restless legs. Acta Med Scand 1953;145:453-457.

10. Trotti LM, Bhadriraju S, Becker LA. Iron for restless legs syndrome. Cochrane Database Syst Rev 2012;5:CD007834.

11. Schneider J, Krafft A, Manconi M, et al. Open-label study of the efficacy and safety of intravenous ferric carboxymaltose in pregnant women with restless legs syndrome. Sleep Med 2015;16:1342-1347.

12. Cho YW, Allen RP, Earley CJ. Clinical efficacy of ferric carboxymaltose treatment in patients with restless legs syndrome. Sleep Med 2016;25:16-23.

13. Walters AS, Ondo WG, Dreykluft T, Grunstein R, Lee D, Sethi K. Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord 2004;19:1414-1423.

14. Trenkwalder C. The weight of evidence for ropinirole in restless legs syndrome. Eur J Neurol 2006;13(Suppl 3):21-30.

15. National Institute of Mental Health. 028 CGI. Clinical Global Impressions. In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health; 1976:217-222.

16. Walters AS, LeBrocq C, Dhar A, et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 2003;4:121-132.

17. Kohnen R, Martinez-Martin P, Benes H, et al. Validation of the Kohnen Restless Legs Syndrome-Quality of Life instrument. Sleep Med 2016;24:10-17.

18. Beard JL. Iron biology in immune function, muscle metabolism and neuronal functioning. J Nutr 2001;131:568S-579S.

19. Giordano FJ. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 2005;115:500-508.

20. Levy P, Pepin JL, Arnaud C, et al. Intermittent hypoxia and sleep-disordered breathing: current concepts and perspectives. Eur Respir J 2008;32:1082-1095.

21. Roffe C. Hypoxia and stroke. Age Ageing 2002;31:10-12.

Supporting Data

Additional Supporting Information may be found in the online version of this article at the publisher's website.

FDG PET, Dopamine Transporter SPECT, and Olfaction: Combining Biomarkers in REM Sleep Behavior Disorder

Sanne K. Meles, MD,[1]* David Vadasz, MD,[2]
Remco J. Renken, PhD,[3] Elisabeth Sittig-Wiegand,[2]
Geert Mayer, MD,[2,9] Candan Depboylu, MD,[2]
Kathrin Reetz, MD,[4] Sebastiaan Overeem, MD, PhD,[5]
Angelique Pijpers, MD, PhD,[5] Fransje E. Reesink, MD,[1]
Teus van Laar, MD, PhD,[1] Lisette Heinen, MD,[1]
Laura K. Teune, MD, PhD,[1] Helmut Höffken, MD,[6]
Marcus Luster, MD,[6] Karl Kesper, PhD,[7]
Sofie M. Adriaanse, PhD,[8] Jan Booij, MD, PhD,[8]
Klaus L. Leenders, MD, PhD,[1]† and
Wolfgang H. Oertel, MD, PhD[2,10]†

[1]Department of Neurology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
[2]Department of Neurology, Philipps-Universität Marburg, Marburg, Germany [3]Neuroimaging Center, Department of Neuroscience, University of Groningen, Groningen, The Netherlands [4]Department of Neurology and JARA-BRAIN Institute Molecular Neuroscience and Neuroimaging, Aachen University, Aachen, Germany [5]Kempenhaeghe Foundation, Sleep Medicine Centre, Heeze, The Netherlands [6]Department of Nuclear Medicine, Philipps-Universität Marburg, Marburg, Germany [7]Department of Internal Medicine, Section Respiratory Diseases, Philipps Universität Marburg, Marburg, Germany [8]Department of Nuclear Medicine, Academic Medical Center, Amsterdam, The Netherlands [9]Hephata Klinik, Schwalmstadt, Germany [10]Institute for Neurogenomics, Helmholtz Center for Health and Environment, München, Germany

ABSTRACT

Background: Idiopathic REM sleep behavior disorder is a prodromal stage of Parkinson's disease and dementia with Lewy bodies. Hyposmia, reduced dopamine transporter binding, and expression of the brain metabolic PD-related pattern were each associated with increased risk of conversion to PD. The objective of this study was to study the relationship between the PD-related pattern, dopamine transporter binding, and olfaction in idiopathic REM sleep behavior disorder.

Methods: In this cross-sectional study, 21 idiopathic REM sleep behavior disorder subjects underwent ^{18}F-fluorodeoxyglucose PET, dopamine transporter imaging, and olfactory testing. For reference, we included ^{18}F-fluorodeoxyglucose PET data of 19 controls, 20 PD patients, and 22 patients with dementia with Lewy bodies. PD-related pattern expression z-scores were computed from all PET scans.

Results: PD-related pattern expression was higher in idiopathic REM sleep behavior disorder subjects compared with controls ($P = 0.048$), but lower compared with PD ($P = 0.001$) and dementia with Lewy bodies ($P < 0.0001$). PD-related pattern expression was higher in idiopathic REM sleep behavior disorder subjects with hyposmia and in subjects with an abnormal dopamine transporter scan ($P < 0.05$, uncorrected).

Conclusion: PD-related pattern expression, dopamine transporter binding, and olfaction may provide complementary information for predicting phenoconversion. © 2017 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

Key Words: idiopathic REM sleep behavior disorder; Parkinson's disease-related pattern; ^{18}F-FDG-PET; dopamine transporter ^{123}I-FP-CIT SPECT; olfaction

Longitudinal studies have shown that >80% of individuals with idiopathic REM sleep behavior disorder (RBD) developed Parkinson's disease (PD) or dementia with Lewy bodies (DLB) on long-term follow-up.[1-5] RBD subjects represent a suitable group to study the